

Liying Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9344096/publications.pdf>

Version: 2024-02-01

70
papers

5,832
citations

186265

28
h-index

102487

66
g-index

75
all docs

75
docs citations

75
times ranked

9859
citing authors

#	ARTICLE	IF	CITATIONS
1	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13
2	Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. <i>Cancer</i> , 2022, 128, 675-684.	4.1	11
3	Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. <i>Cancer Genetics</i> , 2022, 264-265, 50-59.	0.4	5
4	Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?. <i>Modern Pathology</i> , 2022, 35, 1515-1528.	5.5	13
5	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4267-4277.	7.0	4
6	The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response. <i>Human Mutation</i> , 2021, 42, 150-163.	2.5	0
7	Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. <i>Human Mutation</i> , 2021, 42, 223-236.	2.5	81
8	The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 869-877.	2.5	2
9	Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant. <i>European Journal of Human Genetics</i> , 2021, 29, 1103-1109.	2.8	1
10	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
11	Insertion of an SVA element in MSH2 as a novel cause of Lynch syndrome. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 571-576.	2.8	6
12	Abstract 449: A standard operating procedure for the curation of gene fusions. , 2021, , .		0
13	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	6.3	66
14	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	5.2	9
15	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021, 53, 1577-1585.	21.4	44
16	Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT). <i>Blood</i> , 2021, 138, 4387-4387.	1.4	0
17	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 482-490.	2.0	0
18	Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. <i>Human Mutation</i> , 2020, 41, 103-109.	2.5	25

#	ARTICLE	IF	CITATIONS
19	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 368-375.	2.8	25
20	Insertion of an Alu-like element in <i>MLH1</i> intron 7 as a novel cause of Lynch syndrome. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1523.	1.2	4
21	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	1.9	8
22	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , The, 2020, 21, e386-e397.	10.7	237
23	Accurate germline RUNX1 variant interpretation and its clinical significance. <i>Blood Advances</i> , 2020, 4, 6199-6203.	5.2	13
24	Fumarate hydratase c.914T>C (p.Phe305Ser) is a pathogenic variant associated with hereditary leiomyomatosis and renal cell cancer syndrome. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1293.	1.2	1
25	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , 2020, 126, 1995-2002.	4.1	26
26	Characterization of a germline splice site variant MLH1 c.678-3T>A in a Lynch syndrome family. <i>Familial Cancer</i> , 2020, 19, 315-322.	1.9	1
27	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). <i>Blood</i> , 2020, 136, 23-23.	1.4	0
28	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	27.8	295
29	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1989-1994.	1.1	10
30	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. <i>Modern Pathology</i> , 2019, 32, 1551-1562.	5.5	12
31	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 286-295.	1.6	397
32	Toward automation of germline variant curation in clinical cancer genetics. <i>Genetics in Medicine</i> , 2019, 21, 2116-2125.	2.4	27
33	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
34	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. <i>Blood Advances</i> , 2019, 3, 2962-2979.	5.2	110
35	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28
36	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112

#	ARTICLE	IF	CITATIONS
37	A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 79-86.	2.5	4
38	The emerging significance of secondary germline testing in cancer genomics. <i>Journal of Pathology</i> , 2018, 244, 610-615.	4.5	37
39	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. <i>Familial Cancer</i> , 2018, 17, 71-77.	1.9	10
40	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. <i>Familial Cancer</i> , 2018, 17, 225-228.	1.9	17
41	Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 543-550.	2.5	5
42	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	9.4	275
43	Gene-specific criteria for <i>PTEN</i> variant curation: Recommendations from the ClinGen PTEN Expert Panel. <i>Human Mutation</i> , 2018, 39, 1581-1592.	2.5	123
44	Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline <i>CDH1</i> sequence variants. <i>Human Mutation</i> , 2018, 39, 1553-1568.	2.5	138
45	Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. <i>Human Mutation</i> , 2018, 39, 1542-1552.	2.5	40
46	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.	7.1	132
47	Germline <i>SDHA</i> mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	1.2	33
48	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1589.	7.1	139
49	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.	7.4	366
50	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. <i>BMC Medical Genomics</i> , 2017, 10, 33.	1.5	111
51	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. <i>JCO Precision Oncology</i> , 2017, 2017, 1-17.	3.0	209
52	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	286
53	CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice Site. <i>PLoS ONE</i> , 2016, 11, e0165654.	2.5	16
54	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205

#	ARTICLE	IF	CITATIONS
55	A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1267-1275.	9.4	41
56	Characterization of a novel germline <i>PALB2</i> duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	2.5	16
57	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	7.1	270
58	Prevalence and Prognostic Role of <i>BRCA1/2</i> Variants in Unselected Chinese Breast Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0156789.	2.5	30
59	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015, 121, 4382-4388.	4.1	167
60	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
61	<i>BAP1</i> Missense Mutation c.2054 A>T (p.E685V) Completely Disrupts Normal Splicing through Creation of a Novel 5' Splice Site in a Human Mesothelioma Cell Line. <i>PLoS ONE</i> , 2015, 10, e0119224.	2.5	9
62	The germline <i>CDH1</i> c.48 G > C substitution contributes to cancer predisposition through generation of a pro-invasive mutation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2014, 770, 106-111.	1.0	11
63	Immunohistochemical detection of <i>ARID1A</i> in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. <i>Human Pathology</i> , 2014, 45, 2430-2436.	2.0	41
64	Assessment of individuals with <i>BRCA1</i> and <i>BRCA2</i> large rearrangements in high-risk breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 625-634.	2.5	11
65	Expression of androgen receptor and its phosphorylated forms in breast cancer progression. <i>Cancer</i> , 2013, 119, 2532-2540.	4.1	20
66	<i>BRCA1</i> R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 1051-1056.	2.5	12
67	cDNA analysis demonstrates that the <i>BRCA2</i> intronic variant <i>IVS4-12del5</i> is a deleterious mutation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 663, 84-89.	1.0	9
68	A Rapid and Reliable Test for <i>BRCA1</i> and <i>BRCA2</i> Founder Mutation Analysis in Paraffin Tissue Using Pyrosequencing. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 176-181.	2.8	18
69	<i>NF-κB</i> Regulates Androgen Receptor Expression and Prostate Cancer Growth. <i>American Journal of Pathology</i> , 2009, 175, 489-499.	3.8	163
70	Immunohistochemistry versus Microsatellite Instability Testing for Screening Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 301-307.	2.8	177